Antibody-drug conjugate · Kills target cells, directed at delta-like protein 3 (DLL3) · developed by Zai Lab Co.
Zocilurtatug pelitecan is an antibody-drug conjugate made of a humanized IgG1 monoclonal antibody against DLL3, a Notch pathway protein overexpressed on many cancer cell types, linked to a camptothecin derivative. After binding DLL3-expressing tumor cells and being internalized, the camptothecin payload causes their death. It is being studied in small-cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07218146 | Phase 3 | Small-cell Lung Cancer | Recruiting | ZLAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Small-cell Lung Cancer
See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZLAB catalysts and pipeline →